Youn H Kim

13PUBLICATIONS
82CO-AUTHORS
Molecular targetsAutoimmunityPredictive and prognostic markersDental materials and equipmentGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 25, 2026
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Aug 04, 2026
Primary Cutaneous Gamma-Delta T-Cell Lymphoma Complicating Long-Standing Immunosuppressed Dermatomyositis.

|Jul 15, 2025
A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification.

Julia J Scarisbrick, Pietro Quaglino, Sean Whittaker

|Feb 08, 2025
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.

Steven M Horwitz, Tatyana A Feldman, Jing Christine Ye

|Dec 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Francine M Foss, Youn H Kim, H Miles Prince

|Oct 10, 2024
Genetic alteration of class I HLA in cutaneous T-cell lymphoma.

Alexa C Kwang, George E Duran, Sebastian Fernandez-Pol

Pageof 3

Frequent Collaborators

6 joint publications

Michael S Khodadoust

4 joint publications

H Miles Prince

4 joint publications

Kerri E Rieger

4 joint publications

Oleg E Akilov